奥沙利铂和氟尿嘧啶联合贝伐珠单抗对晚期胃癌患者免疫功能、 肿瘤标志物和预后的影响

Effects of Oxaliplatin and Fluorouracil Combined with Bevacizumab onImmune Function, Tumor Markers and Prognosis in Patients with AdvancedGastric Cancer

目的:探讨奥沙利铂和氟尿嘧啶联合贝伐珠单抗对晚期胃癌患者免疫功能、肿瘤标志物和预后的影响。方法:选取2014年3月到2017年5月期间我院收治的晚期胃癌患者62例,根据住院号单双数分为对照组和观察组,各31例。对照组给予奥沙利铂和氟尿嘧啶治疗,观察组在对照组的基础上联合贝伐珠单抗治疗,对比两组临床有效率、免疫功能、肿瘤标志物、不良反应和预后。结果:观察组治疗后的临床有效率较对照组高(P<0.05)。两组治疗后免疫球蛋白(Ig)A、IgG、CD4^(+)/CD8^(+)、CD4^(+)、IgM均升高,且观察组高于对照组(P<0.05),两组治疗后CD8^(+)均降低,且观察组低于对照组(P<0.05)。两组治疗后癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原72-4(CA72-4)均降低,且观察组低于对照组(P<0.05)。观察组的不良反应总发生率较对照组低(P<0.05)。观察组复发率、癌症转移率低于对照组,且3年生存率高于对照组(P<0.05)。结论:奥沙利铂和氟尿嘧啶联合贝伐珠单抗治疗晚期胃癌患者,可有效缓解病情,提高免疫功能,同时还降低不良反应发生率,获得良好的预后。

Objective: To investigate the effect of oxaliplatin and fluorouracil combined with bevacizumab on immune function,tumor markers and prognosis in patients with advanced gastric cancer. Methods: 62 patients with advanced gastric cancer in our hospital from March 2014 to May 2017 were selected, and they were divided into control group and observation group according to even and odd of admission number, 31 cases in each group. The control group was treated with oxaliplatin and fluorouracil, and the observation group was treated with bevacizumab on the basis of the control group. The effective rate, immune function, tumor markers, adverse reactions and prognosis of the two groups were compared. Results: The clinical effective rate of the observation group was higher than that of the control group(P<0.05). After treatment, immunoglobulin(Ig)A, IgG, CD4+/CD8+, CD4+, IgM of the two groups were increased, and the observation group was higher than the control group(P<0.05). After treatment, CD8+of the two groups was decreased, and the observation group was lower than the control group(P<0.05). After treatment, carcinoembryonic antigen(CEA), carbohydrate antigen 199(CA199), carbohydrate antigen 72-4(CA72-4) of the two groups decreased, but the observation group was higher than the control group(P<0.05). The total incidence of adverse reactions of the observation group was lower than that of the control group(P<0.05). The recurrence rate, cancer metastasis rate of the observation group was lower than those of the control group and 3-year survival rate was higher than that of the control group(P<0.05). Conclusion: Fluorouracil, oxaliplatin combined with bevacizumab in the treatment of patients with advanced gastric cancer, can effectively prevent disease progression, can improve immune function, but also reduce the incidence of adverse reactions, to obtain a good prognosis.